We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Brooklyn ImmunoTherapeutics Inc | AMEX:BTX | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.79 | 0 | 01:00:00 |
Delaware
|
001-11460
|
31-1103425
|
(State or Other
Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
140 58th Street, Building A,
Suite 2100
|
|
Brooklyn,
New York
|
11220
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
Common Stock, par value $0.005 per share
|
BTX
|
NYSE American
|
Item 1.01 |
Entry into a Material Definitive Agreement.
|
|
• |
We acquired all of the outstanding equity interests of Parent as the result of the merger of Brooklyn Acquisition Sub, Inc. with and into
Parent, following which Parent, as the surviving corporation, became our wholly owned subsidiary and Novellus became our indirectly owned subsidiary.
|
|
• |
We acquired 25.0% of the total outstanding equity interests of NoveCite, Inc., a Delaware corporation focused on bringing an allogeneic
mesenchymal stem cell (MSC) product to patients with acute respiratory distress syndrome (ARDS), including from COVID-19.
|
Item 2.01. |
Completion of Acquisition or Disposition of Assets.
|
Item 3.02 |
Unregistered Sales of Equity Securities.
|
Item 7.01 |
Regulation FD Disclosure.
|
Item 9.01 |
Financial Statements and Exhibits.
|
(d) |
Exhibits.
|
Exhibit
|
Description
|
|
Agreement and Plan of Acquisition, dated as of July 16, 2021, by and among Brooklyn ImmunoTherapeutics, Inc., Brooklyn
Acquisition Sub, Inc., Novellus LLC, Novellus, Inc., and the Sellers’ Representative.
|
||
Registration Rights Agreement, dated as of July 16, 2021, by and among Brooklyn ImmunoTherapeutics, Inc. and the individuals and
entities named therein.
|
||
Press Release of Brooklyn ImmunoTherapeutics, Inc. dated July 19, 2021
|
||
Presentation of Brooklyn ImmunoTherapeutics, Inc. dated July 19, 2021
|
||
104
|
Cover Page Interactive Data File (embedded within the XBRL document)
|
+ |
Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Brooklyn ImmunoTherapeutics, Inc. hereby undertakes to furnish supplementally
copies of any of the omitted schedules and exhibits upon request by the Securities and Exchange Commission.
|
*
|
Certain information redacted and replaced with “[***]”.
|
BROOKLYN IMMUNOTHERAPEUTICS, INC.
|
||
By:
|
/s/ Howard J. Federoff
|
|
Howard J. Federoff
|
||
Chief Executive Officer and President
|
1 Year Brooklyn ImmunoTherapeut... Chart |
1 Month Brooklyn ImmunoTherapeut... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions